DeepMed Research

Novavax

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 1.5K

Market Cap: $1.7B

Website

Introduction: Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Clinical Trials

Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly Adults

Phase 2

Completed

Conditions: Respiratory Syncytial Virus (RSV)

Interventions: Biological: Saline Placebo
Biological: RSV-F Vaccine

First Posted Date: 2014-10-17

Last Posted Date: 2022-05-27

Lead Sponsor: Novavax

Target Recruit Count: 1599

Registration Number: NCT02266628

Locations: 🇺🇸
Lisa Jackson, Seattle, Washington, United States
🇺🇸
Research Across America, Dallas, Texas, United States
🇺🇸
Nothern California Clinical Research, Redding, California, United States

and more 7 locations

RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.

Phase 2

Completed

Conditions: Respiratory Syncytial Virus Infections

Interventions: Drug: Saline Placebo (0.5mL injection)
Drug: RSV F vaccine (0.5mL injection)

First Posted Date: 2014-09-25

Last Posted Date: 2022-05-27

Lead Sponsor: Novavax

Target Recruit Count: 50

Registration Number: NCT02247726

Locations: 🇺🇸
Meridian Clinical Research, Norfolk, Nebraska, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸
Advanced Specialty Research, Nampa, Idaho, United States

and more 4 locations

A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant

Phase 1

Completed

Conditions: Influenza (Pandemic)

Interventions: Biological: Placebo
Biological: Monovalent Avian Influenza VLP (H7N9)
Biological: Matrix-M1™ adjuvant

First Posted Date: 2014-03-05

Last Posted Date: 2016-09-23

Lead Sponsor: Novavax

Target Recruit Count: 610

Registration Number: NCT02078674

Locations: 🇺🇸
Diablo Clinical Research, Walnut Creek, California, United States
🇺🇸
Miami Research Associates, Miami, Florida, United States
🇺🇸
Coastal Carolina Research, Mt. Pleasant, South Carolina, United States

and more 2 locations

RSV F Dose-Ranging Study in Women

Phase 2

Completed

Conditions: Respiratory Syncytial Virus Infections

Interventions: Biological: Low dose RSV F Antigen
Biological: High dose RSV F Antigen
Biological: Dose 3 of Aluminum Adjuvant
Biological: Dose 4 of Aluminum Adjuvant
Biological: Dose 1 of Aluminum Adjuvant
Biological: Dose 2 of Aluminum Adjuvant
Biological: Placebo

First Posted Date: 2013-10-11

Last Posted Date: 2016-05-26

Lead Sponsor: Novavax

Target Recruit Count: 720

Registration Number: NCT01960686

Locations: 🇺🇸
Wake Research Associates, Raleigh, North Carolina, United States
🇺🇸
Diablo Clinical Research, Walnut Creek, California, United States
🇺🇸
Clincal Research of Atlanta, Stockbridge, Georgia, United States

and more 7 locations

A(H7N9) VLP Antigen Dose Ranging Study With Adjuvant 1

Phase 1

Completed

Conditions: Avian Influenza

Interventions: Biological: Monovalent Avian Influenza VLP (H7N9)
Biological: Placebo
Biological: Adjuvant 1

First Posted Date: 2013-07-12

Last Posted Date: 2014-10-13

Lead Sponsor: Novavax

Target Recruit Count: 280

Registration Number: NCT01897701

Locations: 🇦🇺
Linear Clinical Research, Nedlands, Western Australia, Australia
🇦🇺
CMAX, Adelaide, South Australia, Australia
🇦🇺
Q-Pharm Pty Limited, Herston, Queensland, Australia

RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly

Phase 1

Completed

Conditions: Respiratory Syncytial Virus (RSV)

Interventions: Biological: Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
Biological: Placebo (Day 0 & Day 28); Seasonal TIV (Day 0)
Biological: High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
Biological: Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & day 28)
Biological: High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)

First Posted Date: 2012-10-17

Last Posted Date: 2014-03-05

Lead Sponsor: Novavax

Target Recruit Count: 220

Registration Number: NCT01709019

Locations: 🇺🇸
Jean Brown Research, Salt Lake City, Utah, United States
🇺🇸
Accelovance, Melbourne, Florida, United States
🇺🇸
Research Across America, Dallas, Texas, United States

and more 1 locations

RSV-F Vaccine Dose Ranging Study in Young Women

Phase 2

Completed

Conditions: Respiratory Syncytial Virus (RSV)

Interventions: Biological: Low dose RSV-F Vaccine without Adjuvant
Biological: High dose RSV-F Vaccine with Adjuvant
Biological: High dose RSV-F Vaccine without Adjuvant
Biological: Low dose RSV-F Vaccine with Adjuvant
Biological: Low dose RSV-F Vaccine with Adjuvant [Bedside Mixing]
Biological: Placebo

First Posted Date: 2012-10-11

Last Posted Date: 2014-03-07

Lead Sponsor: Novavax

Target Recruit Count: 330

Registration Number: NCT01704365

Locations: 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States
🇺🇸
Accelovance Rockville, Rockville, Maryland, United States
🇺🇸
Clinical Trials of Texas, San Antonio, Texas, United States

and more 1 locations

A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2

Phase 1

Completed

Conditions: Influenza (Pandemic)

Interventions: Biological: Monovalent Avian Influenza VLP (H5N1); Adjuvant
Biological: Monovalent Avian Influenza VLP (H5N1)
Biological: Saline Placebo

First Posted Date: 2012-05-11

Last Posted Date: 2014-02-06

Lead Sponsor: Novavax

Target Recruit Count: 333

Registration Number: NCT01596725

Locations: 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States
🇺🇸
Miami Research Associates, Miami, Florida, United States
🇺🇸
Broward Research Group, Pembroke Pines, Florida, United States

and more 2 locations

A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 1

Phase 1

Completed

Conditions: Influenza (Pandemic)

Interventions: Biological: Monovalent Avian Influenza VLP (H5N1); Adjuvant
Biological: Saline placebo
Biological: Monovalent Avian Influenza VLP (H5N1)

First Posted Date: 2012-05-09

Last Posted Date: 2014-02-06

Lead Sponsor: Novavax

Target Recruit Count: 333

Registration Number: NCT01594320

Locations: 🇺🇸
Johnson County Clin-Trials, Lenexa, Kansas, United States
🇺🇸
Miami Research Associates, Miami, Florida, United States
🇺🇸
Broward Research Group, Pembroke Pines, Florida, United States

and more 2 locations

A Study to Evaluate the Immune Response and Safety of a Seasonal Virus-Like Particle Influenza Vaccine in Healthy Young Adults

Phase 2

Completed

Conditions: Influenza

Interventions: Biological: Novavax Quadrivalent vaccine
Biological: Novavax Trivalent vaccine
Biological: cTIV

First Posted Date: 2012-03-23

Last Posted Date: 2013-07-18

Lead Sponsor: Novavax

Target Recruit Count: 500

Registration Number: NCT01561768

Locations: 🇦🇺
CMAX, Adelaide, Australia
🇦🇺
Emeritus Research, Melbourne, Australia
🇦🇺
Linear Clinical Research, Perth, Australia

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy